ストックスクリーナーアプリを入手
45.79
8.76%
3.69
プレマーケット:
45.90
0.11
+0.24%
Guardant Health Inc (GH) 最新ニュース
ARK Investment Acquires 173K Shares of Guardant Health (GH) | GH Stock News - GuruFocus
Guardant Health (GH) Stock Surges on FDA Breakthrough Designation - GuruFocus
Why Guardant Health Stock Surged Nearly 9% Higher Today - Yahoo Finance
Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday? - Benzinga
Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers - MSN
Epigenetics Market Anticipated to Achieve 11.8% CAGR - GlobeNewswire Inc.
Guardant Health shares rise following FDA breakthrough designation By Investing.com - Investing.com South Africa
Guardant Health shares rise following FDA breakthrough designation - Investing.com
Guardant Health (GH) Gains as FDA Grants Breakthrough Designation - GuruFocus
Guardant Health gets FDA breakthrough device status for cancer detection test - Seeking Alpha
Guardant Health's Shield Multi-Cancer Test Receives FDA Breakthrough Device Designation - marketscreener.com
Guardant Health’s cancer test earns FDA breakthrough status - Investing.com
Guardant Health (GH) Receives FDA Breakthrough Designation for Cancer Detection Test | GH Stock News - GuruFocus
FDA Grants Breakthrough Device Designation to Guardant Health's - GuruFocus
Groundbreaking FDA Decision: Guardant's Blood Test Can Detect 8 Cancers With 98% Accuracy - Stock Titan
FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test - The Joplin Globe
ARK Investment Acquires 158.7K Shares of Guardant Health (GH) | GH Stock News - GuruFocus
Cathie Wood’s ARK buys Guardant Health, sells Adaptive Biotechnologies stock - Investing.com Nigeria
Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients - MSN
Raymond James reaffirms Guardant Health stock rating after NCCN update By Investing.com - Investing.com Nigeria
Raymond James reaffirms Guardant Health stock rating after NCCN update - Investing.com Australia
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening - BioSpace
Guardant Health (GH) Gains NCCN Approval for Colorectal Cancer Test | GH Stock News - GuruFocus
Guardant Health Announced the results of the Serena-6 Phase III Trial - marketscreener.com
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening | GH Stock News - GuruFocus
SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer - BioSpace
Liquid Biopsy Market for Cancer Detection, cfDNA & CTC Analysis | - openPR.com
Guardant Health (GH) Reveals Key Insights on Colon Cancer Recurrence | GH Stock News - GuruFocus
In Largest Molecular Residual Disease (MRD) Study in Colon Cance - GuruFocus
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions - Yahoo Finance
Guardant Health Inc (GH) Stock Price Up 5.11% on May 30 - GuruFocus
Upcoming Chicago Meeting for Guardant Health (GH) Investors | GH Stock News - GuruFocus
How Delfi Therapeutics plans to make liquid biopsies more accessible - The Business Journals
Guardant Health Inc (GH) Trading Down 3.27% on May 28 - GuruFocus
Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Nuveen Asset Management LLC - Defense World
Guardant Health enhances cancer blood test capabilities By Investing.com - Investing.com South Africa
Firing on All Cylinders: Guardant Health (NASDAQ:GH) Q1 Earnings Lead the Way - Yahoo Finance
Guardant Health enhances cancer blood test capabilities - Investing.com Australia
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test | GH Stock News - GuruFocus
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test - Eagle-Tribune
Ameriprise Financial Inc. Purchases 76,124 Shares of Guardant Health, Inc. (NASDAQ:GH) - Defense World
New Tests Promise to Reveal the Secrets in Your Blood - WSJ
Investor Attention Turns to Biotech as Traditional Cancer Research Models Strain - Baystreet.ca
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting - BioSpace
(GH) Technical Data - news.stocktradersdaily.com
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting | GH Stock News - GuruFocus
Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know - Yahoo Finance
0.46%
1.66%
大文字化:
|
ボリューム (24 時間):